Author

M. Herling

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1

Frequent Co-Authors

C. Kolb· 2 shared C. Wagner· 2 shared F. Grebien· 2 shared H. A. Neubauer· 2 shared H. Sorger· 2 shared M. Dahlhoff· 2 shared R. Fleck· 2 shared R. Moriggl· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Kolb

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma

D. Pölöske, H. Sorger, A. Schönbichler, E. D. de Araujo, H. A. Neubauer, A. Orlova, S. H. Timonen, D. I. Abdallah, A. Ianevski, H. Kuusanmäki, M. Surbek, C. Wagner, T. Suske, M. L. Metzelder, M. Bergmann, , R. Moriggl

This study evaluates small molecule STAT3/5 inhibitors for treating AML and NKCL, showing growth arrest and synergy with existing therapies in vitro and in vivo.

bioRxiv · Oct 12, 2023 · PreprintCancer Biology

STAT5 Gain-of-Function Variants Promote Precursor T-Cell Receptor Activation to Drive T-Cell Acute Lymphoblastic Leukemia

T. Suske, H. Sorger, F. Ruge, N. Prutsch, M. W. Zimmerman, T. Eder, B. Maurer, C. Wagner, S. Schoenefeldt, K. Spirk, A. Pichler, T. Pemovska, C. Schweicker, D. Poeloeske, D. Jungherz, , R. Moriggl

This study identifies STAT5 gain-of-function mutations as drivers of T-ALL by promoting pre-TCR signaling and shows therapeutic targeting potential with STAT3/5 or ZAP70 inhibitors.

bioRxiv · Dec 21, 2022 · PreprintCancer Biology

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

S. A. Herbst, M. Vesterlund, A. J. Helmboldt, R. Jafari, I. Siavelis, M. Stahl, E. Schitter, N. Liebers, B. Brinkmann, F. Czernilofsky, T. Roider, P.-M. Bruch, M. Iskar, A. Kittai, Y. Huang, , Hu

The paper performs a proteogenomic analysis of chronic lymphocytic leukemia, identifies a new poor-prognosis subgroup (ASB-CLL) through proteomic profiling, and links it to clinical outcomes.

bioRxiv · Mar 1, 2022Cancer Biology

Phagocytosis by stroma confounds co-culture studies

S. A. Herbst, M. Stolarczyk, T. Becirovic, Y. Liu, C. Kolb, M. Herling, C. Müller-Tidow, S. Dietrich

The paper shows that bone marrow stromal cells can phagocytose apoptotic cells, potentially leading to misinterpretation of drug response in co-culture studies.

bioRxiv · Dec 11, 2020 · PreprintCancer Biology